Contrasting Avalo Therapeutics (NASDAQ:AVTX) & Opus Genetics (NASDAQ:IRD)

Avalo Therapeutics (NASDAQ:AVTX) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Insider and Institutional Ownership

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Avalo Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Profitability

This table compares Avalo Therapeutics and Opus Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Opus Genetics	-1,091.82%	N/A	-150.13%

Valuation & Earnings

This table compares Avalo Therapeutics and Opus Genetics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60,000.00	6,498.17	-$78.26 million	($2.52)	-2.88
Opus Genetics	$14.20 million	24.45	-$49.59 million	($1.35)	-3.11

Opus Genetics has higher revenue and earnings than Avalo Therapeutics. Opus Genetics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Avalo Therapeutics and Opus Genetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1	2	11	0	2.71
Opus Genetics	1	1	16	1	2.89

Avalo Therapeutics currently has a consensus price target of $36.82, suggesting a potential upside of 406.44%. Opus Genetics has a consensus price target of $12.71, suggesting a potential upside of 202.72%. Given Avalo Therapeutics’ higher probable upside, equities analysts clearly believe Avalo Therapeutics is more favorable than Opus Genetics.

Summary

Opus Genetics beats Avalo Therapeutics on 9 of the 14 factors compared between the two stocks.

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.